Linkedin
RLS logo_header
Linkedin

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

“This collaboration combines Abilita’s strength in discovering breakthrough antibody therapeutics for challenging membrane protein targets with Orion’s proven expertise in oncology and pain, clinical development, and commercialisation,” said Mauro Mileni, Ph.D., founder and CEO of Abilita Therapeutics. “We are excited to leverage our EMP™ platform, the most advanced directed evolution approach, to unlock targets to generate high-value therapeutics. The partnership with Orion allows us to accelerate promising therapeutics into the clinic as part of our broader plan to advance our pipeline.”

Read the full story on "Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics"

Share:

More News

Orphan Drug Designation from the US FDA for Amezalpat to Treat Patients with HCC

“Receiving orphan drug designation for amezalpat to treat HCC underscores the critical need for new treatment options for patients suffering from this historically hard to treat disease,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D of Tempest. “Tempest is dedicated to developing groundbreaking cancer treatments that

Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate

Dr. Samuel Zhang, Chief Business Officer of Innovent, stated: “We are delighted to once again enter a strategic collaboration with Roche, a global leader in oncology, to advance our potentially best-in-class DLL3 ADC candidate. By combining Roche’s scientific expertise and global development capabilities with our innovative approach, we are taking

Investigator-initiated trial (IIT) initiated in China for KJ-C2219 for the treatment of R/R B-NHL

“CARsgen Therapeutics, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the initiation of an investigator-initiated trial (IIT) in China for KJ-C2219, an allogeneic CAR T-cell therapy, targeting CD19/CD20. The trial will evaluate KJ-C2219 for the treatment of relapsed/refractory B-cell non-Hodgkin

FDA Acceptance and Priority Review of NDA for Avutometinib + Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer Announced

“The FDA filing acceptance and Priority Review for the combination of avutometinib and defactinib underscores the critical unmet need among patients diagnosed with this rare and insidious disease. We are excited by today’s news and to potentially bring the first ever FDA-approved treatment specifically for recurrent KRAS mutant LGSOC to

Onco-This-Week

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.